Technology Invasin

In this overview, we describe the Invasin methodology: what it can be used for, how it compares to existing organoid culturing technologies, and its main advantages and limitations.

What is the name of the methodology?

Invasin: Bacterial-expressed Invasin, an integrin-activating Yersinia protein, sustains long-term expansion of primary epithelial cells as 2D organoid sheets.

Developed by the Organoid Group.

What is the methodology good for?

We recently developed a novel organoid 2D sheet platform based on the coating of the bacterial integrin-activating protein of the Enteropathogenic Yersinia bacteria (Invasin). 

Epithelial cells of different origins grow on Invasin in 2D and can be expanded and passaged long-term. In addition, polarization, junction formation and generation of various cell types were stable over time. Invasin, therefore, promises to represent a fully defined, versatile, cheap and animal-free alternative for BME/Matrigel. 

What is/are the main advantages of this methodology over related technologies?

This 2D culturing approach holds practical advantages over the 3D “in gel” format: basal as well as apical domains are directly accessible for infection, uptake, or transport studies, while functional integrity of junctional barriers can readily be assessed. In addition, image analyses and high-throughput (drug) screening approaches are much simpler when executed in 2D.

What are the most important limitations of the methodology?

Not applicable.

What type of samples are compatible with methodology (yes, no, possibly)?

Cancer cell lines

Primary cells in culture

Organoids

Primary tissue 

Not Relevant

Not Relevant

Yes

Yes

What future develops to the methodology are you planning, in any?

Coupling of Invasin to a gel for culturing organoids in 3D.
The generation and usage of image analyses and high-throughput (drug) screening protocols.

If someone outside your lab wants to use the methodology, what is the best option?

Protocols have been published and are continuously optimized. Purified Invasin protein can be obtained upon the signing of an MTA. Experience in how to culture organoids is essential.

Name one or more people in your lab that are experienced with the methodology

Joost Wijnakker and several other members of the Organoid Group.

Who originally developed the methodology?

The usage of Invasin as an alternative for BME/Matrigel for the growth of 2D organoids was developed by Wim de Lau and Joost Wijnakker. 
The method has been published: Joost Wijnakker et al:  doi: 10.1073/pnas.2420595121.

 

 

Confidentiality Statement
This bulletin contains proprietary information intended solely for the designated recipients. Redistribution, forwarding, copying, or any form of disclosing it to third parties- whether in part or in full - is strictly prohibited without the explicit prior written permission of Oncode Institute. By accessing this material, you agree to comply to these confidentiality obligations and to use it solely for its intended informational purpose.

 

LEARN MORE ABOUT

Latest News
Persberichten

Vandaag is de Oncode Impact Foundation gelanceerd, een gezamenlijk initiatief van Stichting Oncode Accelerator en Oncode Institute. De nieuwe stichting zet filantropie in om een cruciale ontbrekende schakel in de ontwikkeling van nieuwe kankerbehandelingen te financieren: de fase waarin veelbelovende wetenschappelijke doorbraken vaak stranden en patiënten nooit bereiken.

Onderzoeksnieuws

Lichtgevende tumoren en zelfgemaakte immuuntherapie: nieuw onderzoek naar zeldzame kanker - Cloned - Cloned - Cloned

Tumoren in de alvleesklier zichtbaar maken tijdens operaties en afweercellen in het lichaam ombouwen tot gerichte aanvallers. Met 2 nieuwe onderzoeken zetten Stichting Kinderen Kankervrij (KiKa), Oncode Institute en KWF Kankerbestrijding in op innovatieve behandelingen voor zeldzame kanker bij volwassenen en kinderen.

Persberichten

Oncode Institute laat in het vandaag gepubliceerde Jaarverslag 2025 zien hoe excellent fundamenteel kankeronderzoek, samenwerking en valorisatie samen leiden tot impact voor patiënten, samenleving en economie. Het aantal mensen met kanker stijgt, de druk op het zorgstelsel neemt toe en de behoefte aan effectieve en betaalbare diagnostiek en behandelingen groeit. Tegelijkertijd beschikt Nederland over kankeronderzoek van wereldklasse. De opgave is om die kennis sneller en beter door te ontwikkelen tot toepassingen die patiënten bereiken.

If you are interested, please contact us.